Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$9.08 and traded as high as C$10.14. Fennec Pharmaceuticals shares last traded at C$10.14, with a volume of 1,834 shares trading hands.

Wall Street Analyst Weigh In

Separately, Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Stock Up 5.2 %

The stock’s fifty day moving average price is C$9.11 and its 200 day moving average price is C$7.82. The stock has a market cap of C$195.55 million, a P/E ratio of -171.77 and a beta of 0.25. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.

Insider Activity at Fennec Pharmaceuticals

In related news, Director Rostislav Christov Raykov sold 10,000 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of C$8.76, for a total transaction of C$87,552.00. In the last 90 days, insiders have sold 13,617 shares of company stock valued at $122,514. Insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.